Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

BACKGROUND: Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high incidence of coronary heart disease (CHD) and stroke, but is little studied thus...

Descripción completa

Detalles Bibliográficos
Autor principal: Meade, Thomas W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57751/
https://www.ncbi.nlm.nih.gov/pubmed/11806795
http://dx.doi.org/10.1186/cvm-2-4-195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57751/
https://www.ncbi.nlm.nih.gov/pubmed/11806795
http://dx.doi.org/10.1186/cvm-2-4-195

Ejemplares similares